Ophthotech Corp (NASDAQ:OPHT) CFO Bruce Peacock sold 6,137 shares of Ophthotech Corp stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $34.77, for a total value of $213,383.49. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Ophthotech Corp (NASDAQ:OPHT) shares after opening at $35.70 moved to $35.84 on last trade day and at the end of the day closed at $33.73. Company price to cash ratio as 4.76. Ophthotech Corp (NASDAQ:OPHT) showed a negative weekly performance of -0.85%.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, provided a corporate update and announced operational and financial results for the fourth quarter and full year ended December 31, 2013. In 2013, Dicerna achieved very substantial financial and operational objectives in our mission to build an innovative drug development company based on the powerful Dicer Substrate RNA interference technology,” commented Douglas M. Fambrough, PhD, Dicerna’s President and CEO. “With the completion of our successful initial public offering, we added significant financial resources to support the development of our pipeline of optimized Dicer Substrate siRNA (DsiRNA?) molecules, which is focused on specific indications in oncology and rare genetic diseases that we can target through the liver.Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares fell -6.16% in last trading session and ended the day on $26.51. DRNA return on equity ratio is recorded as 54.10% and its return on assets is -125.00%.
CorMedix Inc. (nysemkt:CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, announced on March 10, 2014 that it has closed its previously announced registered direct offering of common stock and warrant units for gross proceeds to the Company of $7.4 million. CorMedix Inc. (NYSEMKT:CRMD) shares moved down -5.18% in last trading session and was closed at $2.38, while trading in range of $2.16-$2.56. CorMedix Inc. (NYSEMKT:CRMD) year to date performance is 91.94%.
Even without profits and revenue as in the case of the most recent quarter, Fate Therapeutics Inc (NASDAQ:FATE) seems to be sliding into the zone where investors want it to be. Its attractive product pipeline has meant that even report of a loss and lack of revenue is not keeping traders away from pushing up the stock. The company recently announced fourth quarter loss of 29 cents per share and no revenue, meeting Zacks consensus on earnings, exceeding the $3.51 loss per share noted in the comparable quarter a year ago. Shares of Fate Therapeutics Inc (NASDAQ:FATE) were up 11.64 percent to $12.28 during Wednesday session. Fate Therapeutics Inc (NASDAQ:FATE) weekly performance is -18.18%. On last trading day company shares ended up $9.00. Fate Therapeutics Inc (NASDAQ:FATE) distance from 50-day simple moving average is 12.94%. Analysts mean target price for the company is $14.50.